📜 What This Document Is

This is a Schedule 14D-9 filing. It’s a formal document a company files with the SEC when it’s being acquired through a tender offer.

👉 Why it matters: Its main job is to give shareholders the company’s official recommendation on whether to accept the buyout offer. In this case, it contains an email from Assertio’s CEO to employees explaining the deal.

🏢 The Companies Involved

Assertio Holdings, Inc. (ASRT) is a specialty pharmaceutical company. In simple terms, they develop and sell prescription medicines for conditions like pain and neurology.

Garda Therapeutics, Inc. is the acquiring company, often called the “Parent.” It’s setting up a new subsidiary, Audi Merger Sub, Inc., to execute the purchase.

👉 This is a classic acquisition where a larger entity (Garda) is buying out a public company (Assertio) to take it private.

🤝 The Deal: Acquisition Details

The core of the document is the acquisition agreement. Here’s how it works:

• Offer Price: $18.00 per share in cash, plus one Contingent Value Right (CVR) per share.
• The CVR: This is a "bonus ticket." It gives shareholders the right to potentially receive additional cash payments in the future if certain conditions are met (e.g., future drug sales or milestones).
• Process: Garda will first launch a tender offer to buy all shares. If successful, Assertio will then be merged into Garda’s subsidiary, with Assertio continuing as a privately owned company.

👉 The total package is $18 + a potential future payout. Shareholders must decide if this is a good price for their stock.

📢 The Company's Message (The Email)

This filing specifically includes an email sent to Assertio employees on April 8, 2026.

While the full email isn’t shown in this snippet, its inclusion is significant. It means management is communicating the deal directly to its team, likely highlighting the strategic benefits and reassuring them about the transition.

📅 Key Dates & Process

• Agreement Date: The merger agreement was signed on April 8, 2026.
• Next Step: Garda must launch the tender offer no later than 10 business days after the agreement date.
• Timeline: The offer period will run for at least 20 business days once it starts.

👉 The process is just beginning. Shareholders will soon receive official offer documents to review.

📚 Where to Find More Info

The filing stresses that this is just an announcement. The official, detailed documents are what matter. These will be filed later and available on:

• The SEC’s website (www.sec.gov)
• Assertio’s investor relations page (https://investor.assertiotx.com)

👉 Investors are urged to read those future documents carefully before making any decision to tender their shares.

🧠 The Analogy

Think of this like receiving a formal offer to buy your house. The buyer (Garda) says, “I’ll give you $500,000 cash today (the $18/share), plus a share of the profits if the new restaurant I’m opening next door takes off (the CVR).” This filing is the seller’s (Assertio’s) real estate agent sending a notice saying, “We’ve received this offer, here’s the basic info, and we’ll be sending you the full contract to review soon.”

🧩 Final Takeaway

Assertio has agreed to be acquired by Garda Therapeutics for $18 per share plus a potential future cash bonus (CVR). This document is the company’s first formal communication about the deal to the market and its employees. The next critical step is the official tender offer, where shareholders will have their chance to vote with their shares.